PTO/SB/81 (01-09)

Approved for use through 11/30/2011. OMB 0851-0035 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY OR REVOCATION OF POWER OF ATTORNEY WITH A NEW POWER OF ATTORNEY

AND

Application Number Attached **Filing Date** Attached Attached First Named Inventor Attached Title Art Unit **Examiner Name**

ALLENOT OF CORPEODOLIDENCE ADDRESS	Examile Mane	
CHANGE OF CORRESPONDENCE ADDRESS	Attorney Docket Number Attached	
I hereby revoke all previous powers of attorney given	in the above-identified application.	
A Power of Attorney is submitted herewith.		
I hereby appoint Practitioner(s) associated with the followin Number as my/our attorney(s) or agent(s) to prosecute the Identified above, and to transact all business in the United and Trademark Office connected therewith:	States Patent	
OR I hereby appoint Practitioner(s) named below as my/our att to transact all business in the United States Patent and Tra	torney(s) or agent(s) to prosecute the application identified abo ademark Office connected therewith:	ve, and
Practitioner(s) Name	Registration Number	
Please recognize or change the correspondence add The address associated with the above-mentioned Custom		
OR The address associated with Customer Number: OR	24280	
Firm or Individual Name Choate Hall & Stewart LLP		
Address Two International Place		
City Boston	State MA Zip 02110	
Country US Telephone 617-248-5000	Email patentdocket@choate.com	
I am the: Applicant/Inventor. OR Assignee of record of the entire Interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) (Form PTO/SB/96) submit	litted herewith or tiled on	
	plicant or Assignee of Record Date 3 3/11	
Signature		07
Name FRZIK ANDERSON	Telephone 603 727 71	7-1
Title and Company CHIEF OPERATING OFFICE 2 NOTE: Signatures of all the inventors or assignees of record of the entire inventors.	Interest or their representative(s) are required. Submit multiple forms if	more than one
signature is required, see below*. *Total of forms are submitted.		

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents. P.O. Box 1450, Alexandria, VA 22313-1450. ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

SCHEDULE A

Application No.	Filing Date (Issue Date)	Title	Attorney Docket No.
09/602373	June 23, 2000	GENERATION OF HIGHLY DIVERSE	2009186-0026
(6,410,271)	(June 25, 2002)	LIBRARY OF EXPRESSION VECTORS VIA HOMOLOGOUS RECOMBINATION IN VEAST	
09/602972	June 23, 2000	METHODS FOR SCREENING A HIGHLY DIVERSE LIBRARY OF PROTEINS IN	2009186-0027
		YEAST	
10/112691	March 27, 2002	GENERATION OF HIGHLY DIVERSE LIBRARY OF EXPRESSION VECTORS VIA	2009186-0028
		HOMOLOGOUS RECOMBINATION IN YEAST	
09/603658	June 23, 2000 (June 25, 2002)	HIGHLY DIVERSE LIBRARY OF YEAST EXPRESSION VECTORS	2009186-0030
09/603663	June 23, 2000	HIGH THROUGHPUT GENERATION AND	2009186-0031
(6,406,863)	(June 18, 2002)	SCREENING OF FULLY HUMAN ANTIBODY REPERTOIRE IN YEAST	
10/112612	March 27, 2002	HAPLOID YEAST CELLS TRANSFORMED	2009186-0032
		WITH A LIBRARY OF EXPRESSION	
		VECTORS ENCODING A FULLY HUMAN ANTIBODY REPERTOIRE	
10/792682	March 2, 2004	HIGH THROUGHPUT GENERATION AND	2009186-0033
		SCREENING OF FULLY HUMAN ANTIBODY REPERTOIRE IN YEAST	
09/703399	October 31, 2000	ASSEMBLY AND SCREENING OF HIGHLY	2009186-0034
(6,610,472)	(August 26, 2003)	COMPLEX AND FULLY HUMAN ANTIBODY REPERTOIRE IN YEAST	
10/423495	April 24, 2003	ASSEMBLY AND SCREENING OF HIGHLY	2009186-0035
		COMPLEX AND FULLY HUMAN ANTIBODY REPERTOIRE IN YEAST	

Application No. (Patent No.)	Filing Date (Issue Date)	Title	Attorney Docket No.
10/947610	September 21, 2004	ASSEMBLY AND SCREENING OF HIGHLY COMPLEX AND FULLY HUMAN ANTIBODY REPERTOIRE IN YEAST	2009186-0036
60/403296	August 12, 2002	HIGH THROUGHPUT GENERATION AND AFFINITY MATURATION OF HUMANIZED ANTIBODY	2009186-0038
10/460595	June 11, 2003	HIGH THROUGHPUT GENERATION AND AFFINITY MATURATION OF HUMANIZED ANTIBODY	2009186-0039
11/480037	June 29, 2006	HIGH THROUGHPUT GENERATION AND AFFINITY MATURATION OF HUMANIZED ANTIBODY	2009186-0040
10/071866	February 8, 2002	HIGH THROUGHPUT GENERATION OF HUMAN MONOCLONAL ANTIBODY AGAINST PEPTIDE FRAGMENTS DERIVED FROM MEMBRANE PROTEINS	2009186-0042
10/133978	April 25, 2002	METHODS FOR GENERATING MONOCLONAL ANTIBODY AGAINST FUSION PROTEIN CONTAINING PEPTIDE FRAGMENT DERIVED FROM MEMBRANE PROTEIN	2009186-0044
10/988485	November 12, 2004	METHODS FOR GENERATING MONOCLONAL ANTIBODY AGAINST FUSION PROTEIN CONTAINING PEPTIDE FRAGMENT DERIVED FROM MEMBRANE PROTEIN	2009186-0045
11/593957 (7,700,302)	November 6, 2006 (April 20, 2010)	METHOD FOR GENERATING AND SELECTING ANTIBODIES AGAINST TARGET PROTEIN	2009186-0047
12/713357	February 26, 2010	METHOD FOR GENERATING AND SELECTING ANTIBODIES AGAINST	2009186-0048

December 4, 2008 September 14, 2007 September 12, 2008 July 16, 2010 March 13, 2009 October 21, 2008 April 13, 2001	Application No. Filing Date (Patent No.) (Issue Date)	litle	Attorney Docket No.
December 4, 2008 September 14, 2007 September 12, 2008 March 13, 2009 October 21, 2008 April 13, 2001		TARGET PROTEIN	
September 14, 2007 September 12, 2008 July 16, 2010 March 13, 2009 October 21, 2008 October 21, 2001		NOVEL ABCB5 EPITOPE AND NOVEL	2009186-0053
September 14, 2007 September 12, 2008 July 16, 2010 March 13, 2009 October 21, 2008 April 13, 2001 October 25, 2007		ANTIBODIES THERETO FOR THE	
September 14, 2007 September 12, 2008 July 16, 2010 March 13, 2009 October 21, 2008 April 13, 2001 October 25, 2007		TREATMENT OF CANCER	
September 12, 2008 July 16, 2010 March 13, 2009 October 21, 2008 April 13, 2001 October 25, 2007		RATIONALLY DESIGNED SYNTHETIC	2009186-0006
September 12, 2008 July 16, 2010 March 13, 2009 October 21, 2008 April 13, 2001	•	PREIMMUNE HUMAN ANTIBODY	
September 12, 2008 July 16, 2010 March 13, 2009 October 21, 2008 April 13, 2001		LIBRARY AND USES THEREFOR	
July 16, 2010 March 13, 2009 October 21, 2008 April 13, 2001 October 25, 2007		RATIONALLY DESIGNED, SYNTHETIC	2009186-0007
July 16, 2010 March 13, 2009 October 21, 2008 April 13, 2001 October 25, 2007		ANTIBODY LIBRARIES AND USES	
Harch 13, 2010 March 13, 2009 October 21, 2008 April 13, 2001 October 25, 2007		THEREFOR	
March 13, 2009 October 21, 2008 April 13, 2001 October 25, 2007		ANTIBODY LIBRARIES	2009186-0010
October 21, 2008 April 13, 2001 October 25, 2007		RATIONALLY DESIGNED SYNTHETIC	2009186-0015
October 21, 2008 April 13, 2001 October 25, 2007		ANTIBODY LIBRARIES AND USES	
October 21, 2008 April 13, 2001 October 25, 2007		THEREFOR	
April 13, 2001 October 25, 2007		COMPOSITIONS AND METHODS FOR	2009186-0024
April 13, 2001 October 25, 2007		PRESENTATION OF PROTEINS VIA CELL	
April 13, 2001 October 25, 2007		SURFACE CAPTURE	
October 25, 2007		Genetastic Affinity Maturation	2009186-0055
Lin Call Careford Contains		Generation and Selection of Library of Proteins	2009186-0005
VIA CEII SUITACE CAPIUIE		via Cell Surface Capture	